Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Summary

An expanded access program (EAP): * Allows doctors to give medicine to patients, * Before it is approved by health authorities. This EAP is for: * Quizartinib * Patients with FLT3-ITD mutated AML, * AML that has come back, or * Is resistant to other therapies. A participant will receive quizartinib if: * The doctor submits a request, * The participant is eligible, and * The country allows the EAP.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications